Kyrgyzstan vs Lithuania: Access to anti-retroviral drugs, male
Kyrgyzstan
48.0%
in 2024
Lithuania
50.0%
in 2024
Kyrgyzstan rank
120th
Lithuania rank
117th
Access to anti-retroviral drugs, male over time
- Kyrgyzstan
- Lithuania
How they compare
Lithuania currently reports 50.0% against 48.0% in Kyrgyzstan, a difference of 2.0%.
The two have swapped places 6 times across 25 shared years of data; in 2000 it was Lithuania ahead.
Kyrgyzstan ranks 120th and Lithuania ranks 117th of 141 countries.
Lithuania has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Kyrgyzstan | Lithuania | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 1.8% | 3.5% | 1.7% | Lithuania |
| 2010s | 18.8% | 21.8% | 3.0% | Lithuania |
| 2020s | 42.8% | 43.4% | 0.6% | Lithuania |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, male, Kyrgyzstan or Lithuania?
- Lithuania, at 50.0% against 48.0% in Kyrgyzstan as of 2024.
- What is the difference in access to anti-retroviral drugs, male between Kyrgyzstan and Lithuania?
- 2.0%, with Lithuania ahead.
- How many years of comparable data are there for Kyrgyzstan and Lithuania?
- 25 years are reported by both, from 2000 to 2024.
- How do Kyrgyzstan and Lithuania rank globally for access to anti-retroviral drugs, male?
- Kyrgyzstan ranks 120th and Lithuania ranks 117th of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, male (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult males living with HIV who are receiving antiretroviral therapy.